Unknown

Dataset Information

0

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

ABSTRACT: Medulloblastoma is the most common malignant brain tumor in children. Aberrant activation of the hedgehog signaling pathway is strongly implicated in the development of some cases of medulloblastoma. A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms. Molecular analyses of tumor specimens obtained before treatment suggested that there was activation of the hedgehog pathway, with loss of heterozygosity and somatic mutation of the gene encoding patched homologue 1 (PTCH1), a key negative regulator of hedgehog signaling.

SUBMITTER: Rudin CM 

PROVIDER: S-EPMC5317279 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Medulloblastoma is the most common malignant brain tumor in children. Aberrant activation of the hedgehog signaling pathway is strongly implicated in the development of some cases of medulloblastoma. A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms. Molecular analyses of tumor specimens obtaine  ...[more]

Similar Datasets

Unknown Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
| S-EPMC4254161 | biostudies-literature
Unknown Effect of the sonic hedgehog inhibitor GDC-0449 on an in vitro isogenic cellular model simulating odontogenic keratocysts.
| S-EPMC6320367 | biostudies-literature
Clinical A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
| 2052240 | ecrin-mdr-crc
Unknown Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
| S-EPMC5310713 | biostudies-literature
Unknown In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.
| S-EPMC4891038 | biostudies-literature
Unknown Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
| S-EPMC5856627 | biostudies-literature
Unknown Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model.
| S-EPMC3356655 | biostudies-literature
Unknown Targeted treatment for sonic hedgehog-dependent medulloblastoma.
| S-EPMC4096181 | biostudies-literature
Transcriptomics Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model
2012-04-19 | E-GEOD-37417 | biostudies-arrayexpress
Unknown Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion.
| S-EPMC2586685 | biostudies-literature